Intellectual property specialist Tekcapital invested US$250,000 in the private placement and converted US$210,090 into equity to take its direct stake to about 39%.
The placing was priced at US$0.18(13p) per share, giving Belluscura a post-money valuation of approximately US$3.7mln.
A medical equipment specialist, Belluscura had intended to float on AIM last year but was thwarted by tricky market conditions at the time.
Established in 2015, Belluscura has so far launched three products with two more in development.
Money raised this time will go on the CURV oxygen concentrator and Snap III level of consciousness monitor.
Bob Rauker, Belluscura’s chief executive, said: “The funds will allow Belluscura to continue with its mission to provide premium, proprietary medical devices at affordable prices."